International Society of Paediatric Oncology

Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, GPC3, Private Securities Litigation Reform Act, Forward-looking statement, Congress, Baylor University, Liver cancer, U.S. Securities and Exchange Commission, International Society, SIOP, Colorectal cancer, Warfarin necrosis, Nasdaq, MCRPC, International Society of Paediatric Oncology, Hepatocellular carcinoma, Annual report, Center, Sale, HER2, Cell, COVID-19, Cancer, HCC, Gene, Breast, Baylor College of Medicine, Lung, D, Form 10-K, Research, Patient, Security (finance), IL-6, Center for Cell and Gene Therapy, FDA, Income, Pharmaceutical industry, Vaccine, Medicine

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update.

Key Points: 
  • HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update.
  • In May 2022, the FDA announced a shortage of fludarabine in the U.S. that is affecting the companys clinical trial sites.
  • At the end of the third quarter of 2022, Bellicum had 11 full time equivalent R&D employees, compared to 5 at the end of the third quarter of 2021.
  • Shares Outstanding: As of November 4, 2022, Bellicum had 8,613,527 shares of common stock and 452,000 shares of preferred stock outstanding.

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Friday, August 5, 2022
FDA, U.S. Securities and Exchange Commission, Association, American Association, European Society for Paediatric Oncology, Precision medicine, United Kingdom, HSF1, Forward-looking statement, GLOBE, Private Securities Litigation Reform Act, SEC, Investment, Disease, European Society for Medical Oncology, Security (finance), Research, Patient, International Society of Paediatric Oncology, Neck, Company, Skin, Risk, NASDAQ, Lung, Head, Time, Commencement, Conference, Food, Pharmaceutical industry, Cryptocurrency, IND

Research and development expenses for the second quarter 2022 included $0.3 million in non-cash expenses.

Key Points: 
  • Research and development expenses for the second quarter 2022 included $0.3 million in non-cash expenses.
  • General and administrative expenses for the second quarter 2022 included $0.2 million in non-cash expenses.
  • Net loss for the second quarter of 2022 included $0.5 million in non-cash expenses as well as $0.5 million in non-recurring expenses.
  • Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs.

World Health Organization and St. Jude Children's Research Hospital to dramatically increase global access to childhood cancer medicines

Retrieved on: 
Monday, December 13, 2021
WHO, Global Alliance, Medicine, Degenerative disease, List, Global Initiative, World, World Health Organization, Access, Achievement, Health, Cancer, Science, Survival, International Society of Paediatric Oncology, Diagnosis, UN, Subaru Global Platform, Information, Department, International Society, CEO, National Cancer Intelligence Network, Global Initiative for Emergency and Essential Surgical Care, Parent, Research, Social media, St. Jude Children's Research Hospital, Childhood cancer, Pharmaceutical industry, Vaccine, Health insurance, Hospital, Jude the Apostle, Child, ST

GENEVA and MEMPHIS, Tenn., Dec. 13, 2021 /PRNewswire/ --The World Health Organization and St. JudeChildren's Research Hospital today announced plans to establish a platform that will dramatically increase access to childhood cancer medicines around the world.

Key Points: 
  • GENEVA and MEMPHIS, Tenn., Dec. 13, 2021 /PRNewswire/ --The World Health Organization and St. JudeChildren's Research Hospital today announced plans to establish a platform that will dramatically increase access to childhood cancer medicines around the world.
  • Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8928751-world-health-organizatio...
    The Global Platform for Access to Childhood Cancer Medicines , the first of its kind, will provide an uninterrupted supply of quality-assured childhood cancer medicines to low- and middle-income countries.
  • World Health Organization and St. Jude Children's Research Hospital first collaborated in 2018, when St. Jude became the first WHO Collaborating Centre for Childhood Cancer and committed $15 million for the creation of the Global Initiative for Childhood Cancer.
  • In 2018, St. Jude and the World Health Organization launched the Global Initiative for Childhood Cancer to increase survival rates to 60% by 2030 for the most common forms of childhood cancer.

Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

Retrieved on: 
Saturday, October 23, 2021
Safety, Anemia, CNS, History, International Society, International Society of Paediatric Oncology, GBM, American Association for Cancer Research, SRC, SIOP, Trial of the century, COVID-19, IMT, Mesoblastic nephroma, Therapy, GLOBE, Toxic leukoencephalopathy, EML4-ALK positive lung cancer, MET, Association, Turning Point, Survival, Private Securities Litigation Reform Act, TKI, American Association, Neoplasm, Large-cell lung carcinoma, SEC, ALK, CARE, Profile, Fatigue, ROS1, RECIST, HIV disease progression rates, Patient, Harvard Medical School, Cancer, BID, Neuroblastoma, NASDAQ, Data, Congress, Form 10-Q, Adult, Glioblastoma, Pharmacokinetics, U.S. Securities and Exchange Commission, Molecular Cancer Research, TRK, Pharmaceutical industry, Medical imaging, Generic drug

These data are being presented today at the virtual 53rd Congress of the International Society of Paediatric Oncology (SIOP) being held October 21-24.

Key Points: 
  • These data are being presented today at the virtual 53rd Congress of the International Society of Paediatric Oncology (SIOP) being held October 21-24.
  • These early data for repotrectinib demonstrate encouraging clinical activity in this pediatric patient population, said Mohammad Hirmand, M.D., chief medical officer.
  • The primary objective of the Phase 2 portion of the study is to determine the anti-tumor activity of repotrectinib in pediatric and young adult patients less than 25 years old.
  • The early Phase 1/2 CARE dataset utilizes an August 2, 2021 data cutoff date.

Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

Retrieved on: 
Monday, October 11, 2021
NASDAQ, Private Securities Litigation Reform Act, MET, ROS1, Large-cell lung carcinoma, Harvard Medical School, Therapy, Adult, SAN, Experiment, International Society of Paediatric Oncology, COVID-19, TRK, International Society, Associate, GLOBE, EML4-ALK positive lung cancer, Cancer, Dana–Farber Cancer Institute, SEC, Form 10-Q, U.S. Securities and Exchange Commission, Turning Point, CARE, SIOP, ALK, Congress, SRC, Patient, Pharmaceutical industry, Medicine

Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

Key Points: 
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.

COVID-19 in children with cancer: Severe disease and disrupted treatment

Retrieved on: 
Thursday, August 26, 2021
Population, Hospital for Sick Children (Toronto), University, SIOP, Cancer, Severe acute respiratory syndrome coronavirus 2, Department, University of Melbourne, Family, Survival, Infection, Knowledge, Social media, Physician, The Lancet, NCI-designated Cancer Center, Research, Travel, St. Jude Children's Research Hospital, Disease, Vaccination, Vaccine, Capacity building, National Cancer Institute, Child, Hospital, Awareness, Multimedia, National Cancer Intelligence Network, International Society, Mortality, ALSAC, Risk, International Society of Paediatric Oncology, National, Patient, Adolescence, Nursing, Education, Housing, COVID-19, Hematopoietic stem cell transplantation, Pharmaceutical industry, Medicine

Results from the registry indicated that in addition to more severe or critical infections, pediatric cancer patients were more likely to be hospitalized and die than were other children.

Key Points: 
  • Results from the registry indicated that in addition to more severe or critical infections, pediatric cancer patients were more likely to be hospitalized and die than were other children.
  • "This global collaboration helps clinicians make evidence-based decisions about prevention and treatment, which, unfortunately, remain relevant as the pandemic continues."
  • The analysis looked at 1,500 children from 131 hospitals in 45 countries from April 15, 2020, to February 1, 2021.
  • Vaccination is one way to protect not only yourself but your community, including those who are at high risk of severe disease such as children with cancer.

Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

Retrieved on: 
Monday, August 9, 2021
SRC, Turning Point, TKI, MET, Cancer, Pharmacokinetics, CARE, ROS1, Partnership, Stomach, Safety, Private Securities Litigation Reform Act, Fast Track, COVID-19, Patient, CEO, Compte rendu, ALK, International Society, KRAS, SIOP, NASDAQ, International Society of Paediatric Oncology, Adult, AACR, Food, Adenocarcinoma, Research, Achievement, TRK, GEJ, Molecular Cancer Research, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SEC, Conference, Large-cell lung carcinoma, Hand, Congress, Investment, Discovery, GLOBE, FDA, Â, SAN, Least, NSCLC, EML4-ALK positive lung cancer, D, G&A, IND, Medicine, Pharmaceutical industry, Lithium

Acceptance of TRIDENT-1 clinical data for presentation at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October.

Key Points: 
  • Acceptance of TRIDENT-1 clinical data for presentation at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October.
  • Achievement of the milestones resulted in revenue of $5 million to Turning Point under its collaboration agreement with Zai Lab.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

More Than 300,000 Children are Diagnosed With Cancer Globally, Each Year- SIOP ASIA 2019 Congress

Retrieved on: 
Thursday, April 4, 2019
Health, Childhood cancer, Cancer, Cancer organizations, Medicine, Medical specialties, Oncology, International Society of Paediatric Oncology

Sadly, childhood cancer continues to be the leading cause of non-communicable related death in children throughout the world.

Key Points: 
  • Sadly, childhood cancer continues to be the leading cause of non-communicable related death in children throughout the world.
  • The WHO Global Childhood Cancer Initiative target is to achieve at least 60% survival for all children with cancer by 2030.
  • Childhood Cancer International and SIOP are not alone in recognizing the devastating impact of childhood cancer on children and families around the globe.
  • Childhood Cancer International is committed to advancing cures, transforming care, and instilling hope for all children and adolescents diagnosed with cancer in the world, wherever they may live.

More Than 300,000 Children are Diagnosed With Cancer Globally, Each Year- SIOP ASIA 2019 Congress

Retrieved on: 
Thursday, April 4, 2019
Health, Childhood cancer, Cancer, Cancer organizations, Medicine, Medical specialties, Oncology, International Society of Paediatric Oncology

Sadly, childhood cancer continues to be the leading cause of non-communicable related death in children throughout the world.

Key Points: 
  • Sadly, childhood cancer continues to be the leading cause of non-communicable related death in children throughout the world.
  • The WHO Global Childhood Cancer Initiative target is to achieve at least 60% survival for all children with cancer by 2030.
  • Childhood Cancer International and SIOP are not alone in recognizing the devastating impact of childhood cancer on children and families around the globe.
  • Childhood Cancer International is committed to advancing cures, transforming care, and instilling hope for all children and adolescents diagnosed with cancer in the world, wherever they may live.